title: Outcomes of surgical site infections in orthopedic trauma surgeries in a tertiary care centre in India.
abstract: BACKGROUND
  Surgical site infections (SSIs) still cause significant morbidity and mortality despite advances in trauma care. We have studied in this paper the rate of SSIs, their outcomes in patients undergoing interventions for trauma and SSI trends in developing countries.
  
  
  METHODS
  A 16-month study (May, 2011- August, 2012) was carried out. Patients undergoing interventions for orthopedic trauma were followed and assessed for SSIs and their outcomes and antimicrobial sensitivity patterns of the micro-organisms isolated were noted and correlated.
  
  
  RESULTS
  A total of 40 (4.4%) confirmed cases of SSIs were identified among 852 patients of orthopedic trauma. Based on the new CDC criteria, after ruling out cellulitis, only 24 (2.6%) were found to have SSIs. A total of 12.5% of the SSIs were detected during follow-up. Acinetobacter baumannii was the predominant organism as also Staphylococcus aureus. Outcomes observed included changes in antibiotic regime, revision surgery, readmission to hospital and deaths.
  
  
  CONCLUSIONS
  SSI is prevalent in orthopaedic trauma patients and an active surveillance program will help in early management and prevention.
authors.forename: N
authors.initials: N
authors.lastname: Rajkumari
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.affiliation: Department of Laboratory Medicine (Microbiology Division), Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: P
authors.initials: P
authors.lastname: Mathur
authors.forename: V
authors.initials: V
authors.lastname: Trikha
authors.forename: V
authors.initials: V
authors.lastname: Sharma
authors.forename: K
authors.initials: K
authors.lastname: Farooque
authors.forename: M C
authors.initials: MC
authors.lastname: Misra
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology; D040981:Acinetobacter baumannii / Q000302:isolation & purification; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures / Q000379:methods*; D011159:Population Surveillance; D015995:Prevalence; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology; D013211:Staphylococcus aureus / Q000302:isolation & purification; D013530:Surgical Wound Infection / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D062606:Tertiary Care Centers; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents